Resource Center

Reading Time: 3 minutes Insights from Medidata Experts Mid-sized and emerging biopharma companies drive innovation in clinical trials, originating and launching 40% of new active substances (NAS) in 2020.1 However, lean resources, limited access to sites and patients, lack of integrated systems, and uncertain funding impose restrictions on mid-sized and emerging sponsors and slow the pace of drug development. […]

Article

Reading Time: 3 minutes Insights from Medidata Experts Mid-sized and emerging biopharma companies drive innovation in clinical trials, and their choice of technology plays a critical role in powering this innovation. How can mid-sized and emerging sponsors leverage technology and data to best position themselves for success? This two-part blog series, following a post on general recommendations, brings insights […]

Article

Hello and Welcome to the Week in Review! This is the weekly blog post...

Article

After more than 18 months, COVID-19 remains a major threat around the...

Article